Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.

In clinical routine, adjuvant systemic therapy in small node-negative (N0) BC is controversial, in particular in HER2-positive disease. We aimed to evaluate outcome of consecutive patients with small N0 BC in a population-based cancer registry and thus consequently substantiate indications for chemotherapy in those patient subgroups at increased relapse risk or poor survival. From 2002 to 2009 (median follow-up 6 years), 9707 primary breast cancer patients with N0 tumors <2 cm (pTis, pT1N0M0) were reported to the Munich Cancer Registry. Patients with pTis tumors (n = 1870) served as internal comparator. Time to progression, observed (OS) and relative survival rates (Kaplan-Meier estimates) are presented. Cox regression analysis was used to assess the influence of tumor size, age, HR-, and HER2-status. 10-year-OS for pTis was 94.0%. In HR-positive tumors it was 91.9% in pT1a, 90.6% in pT1b, and 86.8% in pT1c. In HR-negative tumors, rates were 91.7%, 86.8%, and 86.8%, respectively. In HER2-positive tumors it was 81.2%, 88.1%, and 86.7%, in HER2-negative 93.1%, 90.6%, and 86.0%, respectively. In the multivariate model, age, tumor size, and HR-status showed a significant impact on OS (HRneg. vs. HRpos.: hazard ratio 1.50 (95% CI; 1.12-1.99), while HER2-status was not an independent prognostic factor. Prognosis of N0 tumors <1 cm is excellent, especially if they are HR-positive, even in HER2-positive cases. Weighing potential benefits vs. side-effects, there seems to be no need for chemotherapy in tumors <0.5 cm. In pT1b chemotherapy may be considered, if tumors are triple negative or HER2-positive and HR-negative. In pT1c guideline-based adjuvant therapy using all therapeutic options seems to be warranted.

Kolben T ，Harbeck N ，Wuerstlein R ，Schubert-Fritschle G ，Bauerfeind I ，Schrodi S ，Engel J ... -  《-》

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J ，Kanomata N ，Yamashita T ，Shimo T ，Mizutoh A ，Moriya T ，Sonoo H ... -  《-》

T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.

Kaplan HG ，Malmgren JA ，Atwood M 《-》

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.

Curigliano G ，Viale G ，Bagnardi V ，Fumagalli L ，Locatelli M ，Rotmensz N ，Ghisini R ，Colleoni M ，Munzone E ，Veronesi P ，Zurrida S ，Nolè F ，Goldhirsch A ... -  《-》

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX ，Qin QH ，Yang WP ，Mo QG ，Wei CY ... -  《International Journal of Clinical and Experimental Pathology》